Table 4. Survival Outcomes of 440 Patients with Metastatic Prostate Cancer, Stratified According to Site of Metastasis and Presence of Pain.
| Bone metastasis only | Visceral metastasis only | Bone and visceral metastases | ||
|---|---|---|---|---|
| Without pain | With pain | |||
| No. (%) | 152 | 96 | 158 | 34 |
| No. progression to CRPC (%) | 72 (47.4) | 69 (71.9) | 47 (29.7) | 23 (67.6) |
| Time, progression to CRPC (months) | 20.3 (7.7-32.9) | 14.3 (9.1-19.5) | 34.2 (11.9-56.5) | 20.4 (10.5-42.8) |
| No. cancer-specific deaths (%) | 30 (19.7) | 45 (46.9) | 17 (10.8) | 16 (47.1) |
| Time, cancer-specific death (months) | 37.1 (17.9-56.3) | 24.5 (12.6-36.4) | 42.8 (22.5-63.2) | 30.8 (16.7-51.5) |
| Survival (%) | ||||
| CRPC progression-free | ||||
| 2-yr | 65.1 | 34.3 | 87.1 | 50.9 |
| 3-yr | 52.6 | 28.3 | 83.7 | 43.8 |
| Cancer-specific | ||||
| 2-yr | 88.1 | 75.6 | 93.1 | 77.0 |
| 3-yr | 78.2 | 57.8 | 89.1 | 64.6 |
| Follow-up period (months) | 41.0 (28.1-53.9) | 27.3 (16.7-38.9) | 45.0 (23.9-66.1) | 38.7 (21.8-56.1) |
CRPC, castration-resistant prostate cancer; IQR, interquartile range.
Data are number (%) and median (IQR).